223 related articles for article (PubMed ID: 26823709)
1. Relationship of Fas, FasL, p53 and bcl-2 expression in human non-small cell lung carcinomas.
Li Y; Xu KP; Jiang D; Zhao J; Ge JF; Zheng SY
Int J Clin Exp Pathol; 2015; 8(11):13978-86. PubMed ID: 26823709
[TBL] [Abstract][Full Text] [Related]
2. Tissue microarray analysis of Fas and FasL expressions in human non-small cell lung carcinomas; with reference to the p53 and bcl-2 overexpressions.
Myong NH
J Korean Med Sci; 2005 Oct; 20(5):770-6. PubMed ID: 16224150
[TBL] [Abstract][Full Text] [Related]
3. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.
Viard-Leveugle I; Veyrenc S; French LE; Brambilla C; Brambilla E
J Pathol; 2003 Oct; 201(2):268-77. PubMed ID: 14517844
[TBL] [Abstract][Full Text] [Related]
4. bcl-2 and p53 protein expression in non-small cell lung cancers: correlation with survival time.
Ohsaki Y; Toyoshima E; Fujiuchi S; Matsui H; Hirata S; Miyokawa N; Kubo Y; Kikuchi K
Clin Cancer Res; 1996 May; 2(5):915-20. PubMed ID: 9816250
[TBL] [Abstract][Full Text] [Related]
5. Fas expression in renal cell carcinoma accurately predicts patient survival after radical nephrectomy.
Sejima T; Morizane S; Hinata N; Yao A; Isoyama T; Saito M; Takenaka A
Urol Int; 2012; 88(3):263-70. PubMed ID: 22398398
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study).
Toffart AC; Timsit JF; Couraud S; Merle P; Moro-Sibilot D; Perol M; Mastroianni B; Souquet PJ; Girard N; Jeannin G; Romand P; Chatellain P; Vesin A; Brambilla C; Brambilla E
Lung Cancer; 2014 Feb; 83(2):182-8. PubMed ID: 24388706
[TBL] [Abstract][Full Text] [Related]
7. Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival.
Volm M; Koomägi R
Br J Cancer; 2000 May; 82(10):1747-54. PubMed ID: 10817513
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis bcl-2 and p53 expression and their relation to tumour stage in non-small cell lung carcinomas (NSCLC).
Kargi HA; Aktaş S; Sagol O; Ermete S; Akpinar O; Akkoçlu A
Cancer Lett; 1997 Jun; 116(2):185-9. PubMed ID: 9215862
[TBL] [Abstract][Full Text] [Related]
9. Expression of apoptosis regulating proteins identifies stage II and III colon cancer patients with high risk of recurrence.
Belt EJ; Stockmann HB; Delis-van Diemen PM; Bril H; Tijssen M; van Essen HF; Heymans MW; Beliën JA; Carvalho B; Cillessen SA; Meijer GA
J Surg Oncol; 2014 Mar; 109(3):255-65. PubMed ID: 24249458
[TBL] [Abstract][Full Text] [Related]
10. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer.
Borner MM; Brousset P; Pfanner-Meyer B; Bacchi M; Vonlanthen S; Hotz MA; Altermatt HJ; Schlaifer D; Reed JC; Betticher DC
Br J Cancer; 1999 Feb; 79(5-6):952-8. PubMed ID: 10070896
[TBL] [Abstract][Full Text] [Related]
11. The implications of proliferation and apoptosis for lung cancer metastasis.
Volm M; Koomagi R
Oncol Rep; 1999; 6(2):373-6. PubMed ID: 10023008
[TBL] [Abstract][Full Text] [Related]
12. Biological prognostic factors for early stage completely resected non-small cell lung cancer.
Cagini L; Monacelli M; Giustozzi G; Moggi L; Bellezza G; Sidoni A; Bucciarelli E; Darwish S; Ludovini V; Pistola L; Gregorc V; Tonato M
J Surg Oncol; 2000 May; 74(1):53-60. PubMed ID: 10861611
[TBL] [Abstract][Full Text] [Related]
13. bcl-2 oncoprotein in surgically resected non-small cell lung cancer: possibly favorable prognostic factor in association with low incidence of distant metastasis.
Higashiyama M; Doi O; Kodama K; Yokouchi H; Nakamori S; Tateishi R
J Surg Oncol; 1997 Jan; 64(1):48-54. PubMed ID: 9040801
[TBL] [Abstract][Full Text] [Related]
14. Receptor for hyaluronic acid-mediated motility (RHAMM, CD168) expression is prognostically important in both nodal negative and nodal positive large cell lung cancer.
Augustin F; Fiegl M; Schmid T; Pomme G; Sterlacci W; Tzankov A
J Clin Pathol; 2015 May; 68(5):368-73. PubMed ID: 25731190
[TBL] [Abstract][Full Text] [Related]
15. A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer.
Sung WW; Wang YC; Cheng YW; Lee MC; Yeh KT; Wang L; Wang J; Chen CY; Lee H
Clin Cancer Res; 2011 Sep; 17(18):5991-9. PubMed ID: 21807637
[TBL] [Abstract][Full Text] [Related]
16. Induction of Fas expression and augmentation of Fas/Fas ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells.
Sun SY; Yue P; Hong WK; Lotan R
Cancer Res; 2000 Nov; 60(22):6537-43. PubMed ID: 11103825
[TBL] [Abstract][Full Text] [Related]
17. Expression of p63, TTF-1 and Maspin in Non-Small Cell Lung Carcinoma and Their Effect on the Prognosis and Differential Diagnosis.
Yaman B; Nart D; Ekren PK; Çok G; Veral A
Turk Patoloji Derg; 2015; 31(3):163-74. PubMed ID: 26456962
[TBL] [Abstract][Full Text] [Related]
18. Biological markers in non-small cell lung cancer. Retrospective study of 10 year follow-up after surgery.
Carbognani P; Tincani G; Crafa P; Sansebastiano G; Pazzini L; Zoni R; Bobbio A; Rusca M
J Cardiovasc Surg (Torino); 2002 Aug; 43(4):545-8. PubMed ID: 12124571
[TBL] [Abstract][Full Text] [Related]
19. [Expression of Fas, Fas ligand, Fas-associated death domain protein, caspase 8 and mutant P53 protein in esophageal squamous cell carcinoma].
Xue LY; Ren LQ; Luo W; Guan XJ; Zou SM; Zheng S; Bi R; Xie YQ; He ZG; Lü N
Zhonghua Yi Xue Za Zhi; 2007 Jan; 87(3):150-4. PubMed ID: 17425843
[TBL] [Abstract][Full Text] [Related]
20. Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma.
Törmänen U; Eerola AK; Rainio P; Vähäkangas K; Soini Y; Sormunen R; Bloigu R; Lehto VP; Pääkkö P
Cancer Res; 1995 Dec; 55(23):5595-602. PubMed ID: 7585640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
